UK online pharmacy price market.
A reproducible view of published price basis, 30-day evidence freshness and explicitly verified service inclusion across PharmacyScore’s direct UK provider evidence. This baseline makes no trend claim.
August matched-cohort price baseline
Wegovy Pill 25mg had the widest interquartile price spread in the August baseline at £41.03. This is the first preserved edition, so it reports no month-on-month movement.
| Treatment / dose | Observations | Range | Median | Middle 50% | IQR |
|---|---|---|---|---|---|
| Mounjaro 2.5mg | 119 | £128.00–£279.95 | £159.99 | £145.99–£174.99 | £29.00 |
| Mounjaro 5mg | 118 | £153.04–£279.95 | £189.00 | £172.25–£199.68 | £27.43 |
| Mounjaro 7.5mg | 117 | £200.00–£323.75 | £245.00 | £229.00–£254.99 | £25.99 |
| Mounjaro 10mg | 118 | £189.00–£379.95 | £275.00 | £252.46–£279.99 | £27.53 |
| Mounjaro 12.5mg | 117 | £245.03–£422.50 | £294.99 | £270.00–£304.00 | £34.00 |
| Mounjaro 15mg | 118 | £209.00–£449.95 | £305.00 | £294.99–£319.99 | £25.00 |
| Wegovy injection 0.25mg | 118 | £75.00–£169.95 | £102.00 | £99.00–£119.99 | £20.99 |
| Wegovy injection 0.5mg | 118 | £79.99–£200.00 | £119.99 | £109.99–£130.00 | £20.01 |
| Wegovy injection 1mg | 119 | £79.99–£200.00 | £130.00 | £118.00–£149.50 | £31.50 |
| Wegovy injection 1.7mg | 118 | £117.00–£225.00 | £169.99 | £159.00–£180.00 | £21.00 |
| Wegovy injection 2.4mg | 117 | £135.00–£289.99 | £199.99 | £189.99–£225.00 | £35.01 |
| Wegovy injection 7.2mg | 80 | £199.88–£379.00 | £258.99 | £239.00–£279.99 | £40.99 |
| Wegovy Pill 1.5mg | 42 | £87.49–£160.00 | £109.99 | £99.00–£129.00 | £30.00 |
| Wegovy Pill 4mg | 37 | £97.95–£179.00 | £119.99 | £117.97–£139.99 | £22.02 |
| Wegovy Pill 9mg | 37 | £113.95–£219.00 | £149.00 | £133.98–£169.00 | £35.02 |
| Wegovy Pill 25mg | 33 | £158.95–£269.00 | £199.00 | £187.97–£229.00 | £41.03 |
Stable matched cohort
A provider enters a treatment cohort when at least one dose has an exact numeric price and direct-dose-price-match evidence in the preserved edition snapshot. Future editions compare only providers present in both editions; additions and removals are reported separately from matched-cohort price movement.
Provider changes
Provider additions and removals are not applicable to this first edition. Future editions report them separately from matched-cohort price movement.
Price basis
Standard, starting and programme provider counts are stored separately in the downloadable edition. An introductory basis is not treated as a standard price.
Limitations: Published prices are observations, not quotes or guarantees of stock, eligibility or suitability. Missing delivery, consultation or programme fees are not assumed to be zero. The baseline describes published provider evidence and does not claim complete UK market coverage. No month-on-month movement is claimed for the first edition.
What the current evidence covers
Counts below use the same active snapshot as the public comparison. A service is counted only where a linked source explicitly confirms inclusion; unverified is not converted to No.
| Treatment | Providers / exact prices | Price basis | Observed within 30 days | Verified included services | Evidence |
|---|---|---|---|---|---|
| Mounjaro | 120 provider sites with exact prices 707 dose prices | 113 standard 1 starting 6 programme | 120 of 120 current provider sites | 1 consultation 1 cold-chain delivery 1 follow-up reviews | Open row-level comparison |
| Wegovy injection | 119 provider sites with exact prices 670 dose prices | 112 standard 1 starting 6 programme | 119 of 119 current provider sites | 0 consultation 0 cold-chain delivery 0 follow-up reviews | Open row-level comparison |
| Wegovy Pill | 43 provider sites with exact prices 166 dose prices | 38 standard 0 starting 5 programme | 43 of 43 current provider sites | 0 consultation 0 cold-chain delivery 0 follow-up reviews | Open row-level comparison |
Measured evidence, with missing coverage left visible.
Included
Exact dose-price matches from provider-owned pages, their recorded price basis and service fields backed by an explicit linked source.
Not inferred
Missing service evidence is not treated as No. Price does not establish stock, suitability, clinical quality, prescribing outcome or recommendation.
Future editions
Cohort and price movement will be reported only after a comparable archived edition exists, with provider additions, removals and corrections disclosed.
See the editorial standard, content-rights notice and corrections route.